title: Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.
abstract: Preclinical studies have convincingly demonstrated a role for the mineralocorticoid receptor (MR) in adipose tissue physiology. These studies show that increased MR activation causes adipocyte dysfunction leading to decreased production of insulin-sensitizing products and increased production of inflammatory factors, creating an environment conducive to metabolic and cardiovascular disease. Accumulating data also suggest that MR activation may be an important link between obesity and metabolic syndrome. Moreover, MR activation may mediate the pathogenic consequences of metabolic syndrome. Recent attempts at reversing cardiometabolic damage in patients with type 2 diabetes using MR antagonists have shown promising results. MR antagonists are already used to treat heart failure where their use decreases mortality and morbidity over and above the use of traditional therapies alone. However, more data are needed to establish the benefits of MR antagonists in diabetes, obesity, and metabolic syndrome.
authors.affiliation: Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA, 02115, USA.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Garg
authors.forename: Gail K
authors.initials: GK
authors.lastname: Adler
mesh_terms: D000450:Aldosterone / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D024821:Metabolic Syndrome / Q000150:complications / Q000503:physiopathology; D009765:Obesity / Q000150:complications; D018161:Receptors, Mineralocorticoid / Q000378:metabolism*; D012307:Risk Factors
chemical_list: D018161:Receptors, Mineralocorticoid; D000450:Aldosterone